Millions of people worldwide suffer from neurodegenerative diseases that impair memory, focus and thinking and impact their ability to go about their daily lives. By applying our novel approach, we believe the synaptic dysfunction responsible for disease symptoms and progression can be reversed before the death of nerve cells.
Our Approach
HOPE THROUGH SCIENCE
We are developing neflamapimod – an investigational, orally administered, small molecule brain penetrant that inhibits the protein kinase p38 alpha. Extensive research has shown that p38 alpha is a key driver of synaptic dysfunction, the reversible aspect of the neurodegenerative process. The preclinical and clinical data with neflamapimod, including our ongoing Phase 2 RewinD-LB trial in patients with dementia with Lewy bodies (DLB), suggest that inhibition of p38 alpha by neflamapimod reverses the synaptic dysfunction that underlies development of symptoms and disease progression in the early stages of many neurological disorders.
PipelineNew analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer’s disease (AD) co-pathology — experienced greater clinical benefit with
Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026 Obtained alignment with FDA and global regulators for planned Phase 3 trial
Data further support choice of patient population and dosing regimen in CervoMed's planned Phase 3 trial in dementia with Lewy bodies (DLB) DLB is the second most common progressive dementia,
